Investigations of direct labeling of anti-VEGF-Mab with Re-188

摘要

Our aim was to establish a reproducible method for labeling an antiVEGF-Mab (anti vascular endothelial growth factor monoclonal antibody) with ~(188)Re and obtaining in house the radiotherapeutic agent ~(188)Re-antiVEGF-Mab ready to use for targeted therapy of cancer. We have developed a simple and efficient procedure for labelling antiVEGF-Mab with ~(188)Re at tracer levels. The method is simple, efficient and reproducible and requires basic facilities that usually exist in nuclear medicine units. This paper presents preliminary in vitro and in vivo testing of ~(188)Re-anti-VEGF aiming to check the specific uptake, the saturation binding concentration, to determine the critical organs and also the therapeutically efficient doses to be administered.